S&P Futures
4,360.50 -43.25 (-0.98%) Dow Futures
34,002.00 -251.00 (-0.73%) Nasdaq Futures
14,318.50 -182.50 (-1.26%) Russell 2000 Futures
2,007.90 -23.80 (-1.17%) Crude Oil
83.64 +0.33 (+0.40%) Gold
1,842.50 +0.80 (+0.04%)
Lexicon Pharmaceuticals, Inc. (LXRX)
After hours:
Chart Events
Performance Outlook
| Previous Close | 3.1500 |
| Open | 3.0700 |
| Bid | 3.1400 x 1000 |
| Ask | 3.1400 x 1800 |
| Day's Range | 2.9150 - 3.1600 |
| 52 Week Range | 2.9150 - 9.6500 |
| Volume | |
| Avg. Volume | 657,578 |
| Market Cap | 466.045M |
| Beta (5Y Monthly) | 1.38 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.4870 |
| Earnings Date | Mar 08, 2022 - Mar 14, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 13.00 |
Fair Value
Related Research
- Lexicon Pharmaceuticals, Inc.CYTK: Lowering target price to $35.00CYTOKINETICS INC has an Investment Rating of HOLD; a target price of $35.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.RatingFair ValueEconomic Moat6 days agoArgus Research
- GlobeNewswire
Lexicon Pharmaceuticals Outlines Major Potential Value Drivers for 2022 at 40th Annual J.P. Morgan Healthcare Conference
NDA submitted for sotagliflozin in heart failure with an expected launch in 2H 2022, if approved LX9211 neuropathic pain Phase 2 studies expected to read out in 1H 2022 THE WOODLANDS, Texas, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) is outlining major potential value drivers for 2022 at this morning’s presentation at the 40th Annual J.P. Morgan Healthcare Conference. Lexicon submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA)
- GlobeNewswire
Lexicon Pharmaceuticals to Participate in The 40th Annual J.P. Morgan Healthcare Conference
THE WOODLANDS, Texas, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Lonnel Coats, Lexicon’s chief executive officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 at 10:30 a.m. ET. A webcast of the event will be available in the “Events” section of the Lexicon website at www.lexpharma.com. An archived version of the webcast will be available on the website for two weeks. About Lexicon Pharmace
- Zacks
Lexicon (LXRX) Submits NDA to the FDA for Cardiovascular Drug
Lexicon (LXRX) submits an application to the FDA seeking approval for sotagliflozin to lower the risk of cardiovascular death and hospitalization and urgent visits for heart failure in adult patients.
